MYC and chronic myelogenous leukemia, BCR-ABL1 positive: Finally, independent studies showed that maintenance of the leukemic stem cell compartment in CML required both MYC [301] and Oxphos activity, and was compromised by tigecycline treatment [302]: we surmise that MYC may also contribute to tigecycline sensitivity in CML stem cells.